Changeflow GovPing Pharma & Drug Safety Synthetic DNA Vectors and Methods of Use
Routine Notice Added Final

Synthetic DNA Vectors and Methods of Use

Favicon for changeflow.com ChangeBridge: EPO Bulletin - Biotech (C12N)
Published March 25th, 2026
Detected April 1st, 2026
Email

Summary

The European Patent Office published patent application EP3765023A1 for Aldevron LLC covering synthetic DNA vectors and their methods of use. The patent relates to genetic engineering applications with IPC classifications in pharmaceutical compositions (A61K) and molecular biology methods (C12N). The application designates all European member states as covered jurisdictions.

What changed

The EPO published patent EP3765023A1 for Aldevron LLC titled 'Synthetic DNA Vectors and Methods of Use.' The patent covers genetic engineering vectors and methodologies, with inventors SCHNEPP and JOHNSON. The application received an A1 publication type indicating a published European patent application with search report. The designated states cover major European markets including DE, FR, GB, IT, ES, NL, and 27 additional EPC contracting states.

This is a routine patent publication notification with no compliance obligations for third parties. Organizations developing genetic engineering, gene therapy, or synthetic biology products should review this patent to assess potential licensing requirements or freedom-to-operate considerations. Patent monitoring services should flag this publication for IP clearance analysis if relevant to ongoing research programs.

Source document (simplified)

← EPO Patent Bulletin

SYNTHETIC DNA VECTORS AND METHODS OF USE

Publication EP3765023A1 Kind: A1 Mar 25, 2026

Applicants

Aldevron, LLC

Inventors

SCHNEPP, Bruce, C., JOHNSON, Philip, R.

IPC Classifications

A61K 31/513 20060101AFI20211213BHEP A61K 48/00 20060101ALI20211213BHEP C12N 15/85 20060101ALI20211213BHEP A61K 31/711 20060101ALI20211213BHEP

Designated States

AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR

View original document →

Source

Analysis generated by AI. Source diff and links are from the original.

Classification

Agency
EPO
Published
March 25th, 2026
Instrument
Notice
Legal weight
Non-binding
Stage
Final
Change scope
Minor
Document ID
EP3765023A1

Who this affects

Applies to
Pharmaceutical companies Drug manufacturers
Industry sector
3254 Pharmaceutical Manufacturing 3254.1 Biotechnology 6211 Healthcare Providers
Activity scope
Patent Licensing Biotechnology Research Gene Therapy Development
Geographic scope
European Union EU

Taxonomy

Primary area
Intellectual Property
Operational domain
Legal
Topics
Biotechnology Pharmaceuticals Healthcare

Get Pharma & Drug Safety alerts

Weekly digest. AI-summarized, no noise.

Free. Unsubscribe anytime.

Get alerts for this source

We'll email you when ChangeBridge: EPO Bulletin - Biotech (C12N) publishes new changes.

Optional. Personalizes your daily digest.

Free. Unsubscribe anytime.